# Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a Pharmaceutical based in San Diego, United States.

## Overview

- **Organization type:** Pharmaceutical
- **Headquarters:** San Diego, United States
- **Region:** North America
- **Address:** San Diego, CA, United States
- **Founded:** 2008
- **Assets under management:** Undisclosed
- **Website:** crinetics.com
- **LinkedIn:** https://www.linkedin.com/company/crinetics-pharmaceuticals

## Regulatory record

- **Reports private funds:** No

## About

Crinetics Pharmaceuticals is a San Diego-based pharmaceutical company founded in 2008. It focuses on developing novel therapeutics targeting peptide hormone receptors for endocrine-related diseases and cancers. The company has secured $460 million in total funding.

## Sectors

- Biotechnology
- Pharmaceuticals

## People

- Scott Struthers — Founder, President and Chief Executive Officer

## Questions

### What is Crinetics' lead clinical asset and its current regulatory status?

Crinetics' most advanced compound is paltusotine, an oral somatostatin receptor type 2 agonist being developed for acromegaly and carcinoid syndrome. The company submitted a New Drug Application to the FDA for the acromegaly indication, which was accepted for review in early 2025. The carcinoid syndrome trial is ongoing under a Phase 3 clinical program.

### How is Crinetics funded given it has no commercial-stage products yet?

Crinetics funds operations through a combination of IPO proceeds, follow-on equity offerings, and at-the-market sales programs. As of December 31, 2024, the company held $839.8 million in cash, cash equivalents and investment securities. In February 2025, Crinetics priced a follow-on stock offering expected to add roughly $500 million in gross proceeds, per its SEC filings.

### What therapeutic areas does Crinetics focus on?

The firm targets endocrine diseases and endocrine-related tumors, a relatively concentrated field within the broader rare-disease landscape. Its disclosed programs focus on acromegaly, carcinoid syndrome from neuroendocrine tumors, congenital adrenal hyperplasia and Cushing's disease.

### Does Crinetics partner with larger pharmaceutical companies for development?

As of the most recent public disclosures, Crinetics has advanced its lead program without a large-cap pharmaceutical partner, maintaining global commercial rights to paltusotine. The company has not reported any co-development or profit-sharing agreements with other biopharmaceutical firms for its lead assets, distinguishing it from the typical out-license model common in rare-disease biotech.

## Related profiles

- [Dance One Holdings](https://altss.com/profile/dance-one-holdings)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/crinetics-pharmaceuticals

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology